Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients With Endometrial Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
Clin. Cancer Res 2023 Jun 26;[EPub Ahead of Print], A Oaknin, B Pothuri, L Gilbert, R Sabatier, J Brown, S Ghamande, C Mathews, DM O'Malley, R Kristeleit, V Boni, A Gravina, S Banerjee, R Miller, J Pikiel, MR Mirza, N Dewal, G Antony, Y Dong, E Zografos, J Veneris, AV TinkerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.